Renal Cell Carcinoma News and Research RSS Feed - Renal Cell Carcinoma News and Research

Renal cell carcinoma (RCC, also known as hypernephroma) is a kidney cancer that originates in the lining of the proximal convoluted tubule, the very small tubes in the kidney that filter the blood and remove waste products.
CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun a new Phase Ib/II clinical trial using a new immunotherapy treatment for patients with advanced kidney, non-small cell lung cancer, pancreatic cancer and colorectal carcinoma. [More]
IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced an independent data monitoring committee (IDMC) has recommended the continuation of the company’s pivotal phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC) following the first of three planned interim data analyses. [More]
Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

Results of two clinical trials reported at the American Society for Clinical Oncology Annual Meeting 2015 show continued promise of immune therapies nivolumab and pembrolizumab against advanced melanomas, specifically in the context of PD1 signaling that some tumors use to avoid immune system attack. Dr. Rene Gonzalez, MD, investigator at the University of Colorado Cancer Center and director of the Melanoma Research Clinics at the CU School of Health, is an author of both studies. [More]
Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone. [More]
AstraZeneca presents preliminary data from AZD6094-AZD9291 combination trial for treatment of NSCLC

AstraZeneca presents preliminary data from AZD6094-AZD9291 combination trial for treatment of NSCLC

Hutchison China MediTech Limited, today announces that AstraZeneca AB, Hutchison MediPharma Limited's collaboration partner, presented preliminary data from the ongoing Phase Ib clinical trial of HMP's c-Met inhibitor savolitinib (AZD6094) combined with AstraZeneca's drug candidate AZD9291 in non-small cell lung cancer. [More]
Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from five studies that demonstrate the clinical utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in helping to identify targeted treatment options for patients with rare and/or aggressive tumors. [More]
Research shows HEOR data can be used to better determine value-based reimbursement strategies

Research shows HEOR data can be used to better determine value-based reimbursement strategies

Later this week, Cardinal Health Specialty Solutions will present a new series of health economic outcomes research (HEOR) studies that reinforce the importance of evaluating real-world treatment patterns when developing value-based reimbursement strategies. [More]
Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14. [More]
Updated data from PROCLAIM national patient registry presented at 51st ASCO

Updated data from PROCLAIM national patient registry presented at 51st ASCO

Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies. [More]
‘Real-world’ sunitinib findings support trial results

‘Real-world’ sunitinib findings support trial results

Results of postmarketing follow-up in Japanese patients confirm the efficacy and safety profile of sunitinib in advanced renal cell carcinoma. [More]
SNPs predict sunitinib outcome in mRCC

SNPs predict sunitinib outcome in mRCC

Research has confirmed that single nucleotide polymorphisms in genes related to the processing of sunitinib influence the outcome of treatment for metastatic renal cell carcinoma. [More]
RCC benefit independent of sorafenib, sunitinib sequence order

RCC benefit independent of sorafenib, sunitinib sequence order

Sequential treatment with sorafenib followed by sunitinib is not superior to sunitinib followed by sorafenib in patients with advanced or metastatic renal cell carcinoma, suggests research published in European Urology. [More]

First-line axitinib ‘feasible’ in advanced, metastatic RCC

A Japanese single-institution study suggests that axitinib may be a feasible first-line option for patients with locally advanced or metastatic renal cell carcinoma. [More]
Honokiol extract holds promise as adjunct treatment for bladder and kidney cancers

Honokiol extract holds promise as adjunct treatment for bladder and kidney cancers

The botanical extract honokiol, a biologically active molecule isolated from the bark of Magnolia spp., holds promise as an adjunct treatment for aggressive bladder and kidney cancers, as reported in two new studies. New research on honokiol in bladder cancer was presented at the American Association for Cancer Research Annual Meeting 2015. [More]
UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

The University of New Mexico Cancer Center recently enrolled its first patient in a phase 3 international clinical trial to test a personalized vaccine against metastatic kidney cancer. Kidney cancer has proven particularly difficult to treat with chemotherapy, and numerous attempts to create a kidney cancer vaccine have not improved survival rates. [More]
Bionomics to present BNC105 trial results of metastatic renal cancer at Asian Oncology Summit

Bionomics to present BNC105 trial results of metastatic renal cancer at Asian Oncology Summit

Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced that it will present a poster with new data on the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the 7th Asian Oncology Summit being held from April 10-12, 2015 in Shanghai, China. [More]
Limited anticancer role for preoperative statins in localised RCC setting

Limited anticancer role for preoperative statins in localised RCC setting

Statin use prior to undergoing nephrectomy is not associated with survival outcomes in patients with localised renal cell carcinoma, research suggests. [More]
IMDC prognostic model valid in second-line RCC therapy

IMDC prognostic model valid in second-line RCC therapy

The International Metastatic Renal Cell Carcinoma Database Consortium prognostic model can be applied to metastatic renal cell carcinoma patients receiving second-line targeted treatment, according to research published in The Lancet Oncology. [More]
Alternating sunitinib, everolimus not supported in advanced RCC

Alternating sunitinib, everolimus not supported in advanced RCC

Australian researchers report that an alternating regimen of sunitinib and everolimus, although feasible and low-risk in patients with advanced renal cell carcinoma, failed to meet the prespecified criteria for use or continued development. [More]
HRQoL benefit of alternative sunitinib dosing schedule in RCC patients

HRQoL benefit of alternative sunitinib dosing schedule in RCC patients

Patients with metastatic renal cell carcinoma reported a marked improvement in their health-related quality of life when given sunitinib on a 2 weeks on and 1 week off schedule compared with a 4 weeks on and 2 weeks off regimen, a Japanese study finds. [More]
Advertisement